Healthcare

Ares leads on Baird Capital’s life sciences single-asset CV

The continuation fund for Blue Matter Consulting is ‘one of those CVs that’s happening for the right reasons’, says Baird partner Michael Holgate.

How we conducted Secondaries Investor’s Global Market Survey

Our inaugural survey takes the temperature of LP, GP, buyer and provider attitudes towards this fast-growing market.

Download Secondaries Investor’s Global Market Survey

Secondaries Investor’s inaugural survey of LPs, secondaries buyers, GPs and advisers offers a complete view of the market and the direction it’s heading in. Conducted in partnership with Goodwin.

Healthcare-focused PE firm Linden mulls secondaries strategy

The Chicago-headquartered firm joins a growing number of buyout firms entering the secondaries market, and is the latest sector-specialist.

Former CVC MD Jonathan Au joins Revelation Partners

Secondaries Investor had reported that Jonathan Au had departed CVC in June last year, having joined the firm in 2021.

Deglobalisation: Alternative assets in a less integrated world

With globalisation in retreat, the implications for private investment are complex. In areas like manufacturing, the push is toward reshoring of portfolio company operations. In risk management, many investors see diversifying their global exposure as key.

ADIA takes lead on over $200m CV in latest GP-led secondaries play

ADIA has backed Beijing-based GL Capital’s single-asset CV just months after it emerged as a co-lead buyer on Tikehau Capital’s continuation fund.

ICG makes public-to-private CV play in TowerBrook, CD&R de-listing deal

The $1.2bn secondaries transaction involves R1 RCM, a healthcare sector revenue cycle management services provider.

AlpInvest leads €600m GP-led on specialty pharma asset

Swiss GP Gyrus Capital originally invested in Essential Pharma in 2019 as part of a family/founder succession plan process.

Morgan Stanley, Hayfin back CV on Nordic GP Impilo-owned healthcare asset

KKR bought a portion of the asset through a separate M&A process, which is understood to have been used to anchor pricing that the Evercore-advised CV transaction was based off.